Association of Polypharmacy and Burden of Comorbidities on COVID-19 Adverse Outcomes in People with Type 1 or Type 2 Diabetes
We have shown in T2DM an independent association of multiple medications taken from 11 upwards with adverse health consequences following COVID-19 infection. We also found that individuals with diabetes develop comorbidities that were common across both T1DM and T2DM. This study has laid the foundation for future investigations into the way that complex pharmacological interactions may influence clinical outcomes in people with T2DM.
Authors
- Darren Mark Ashcroft (ORCID: https://orcid.org/0000-0002-2958-915X)
- Juhi Gupta (ORCID: https://orcid.org/0000-0002-8292-9846)
- Rathi Ravindrarajah (ORCID: https://orcid.org/0000-0003-4875-4912)
- George Tilston (ORCID: https://orcid.org/0000-0003-1475-5888)
- Adrian Hugh Heald (ORCID: https://orcid.org/0000-0002-9537-4050)
- William Ollier
Institutions
- Manchester Metropolitan University (GB)
- Manchester Academic Health Science Centre (GB)
- Salford Royal NHS Foundation Trust (GB)
- University of Manchester (GB)
Publication Details
- Journal
- Diabetes Therapy
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1007/s13300-024-01681-9
- Primary Topic
- Pharmaceutical Practices and Patient Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Turing Foundation